Multiple Treatments for COVID-19

(CATCO Trial)

Recruiting in Palo Alto (17 mi)

+52 other locations

Overseen by Srinivas Murthy, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Sunnybrook Health Sciences Centre

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This trial tests various drugs on hospitalized COVID-19 patients to see if they work better than standard treatments. The drugs aim to reduce inflammation, block harmful proteins, or kill viruses. Remdesivir has been studied extensively for its antiviral properties and was initially developed for treating Ebola virus.

Research Team

Srinivas Murthy, MD

Principal Investigator

Provincial Health Services Authority

Eligibility Criteria

Adults hospitalized with acute COVID-19 infection, confirmed by a lab test within the last 14 days. Participants must be at their first hospital admission for COVID-19 and not expected to transfer to a non-participating center or pass away within 24 hours. Exclusions include known allergies to trial drugs, certain pre-existing conditions, pregnancy, breastfeeding, and current use of study drugs.

Inclusion Criteria

I am in the hospital primarily due to COVID-19.

Randomization WHO will have no other specific inclusion criteria

This is my first hospital visit for COVID-19.

Exclusion Criteria

It is expected that the person will not live for more than 24 hours.

I do not have severe heart failure, tuberculosis, or allergies to infliximab.

Known hypersensitivity or prior use of LSALT peptide; pregnant or breastfeeding for Randomization LSALT

Treatment Details

Interventions

• ARBs (ARBs)
• Artesunate (Antimalarial)
• Dexamethasone (Corticosteroid)
• Imatinib (Tyrosine Kinase Inhibitor)
• Infliximab (Monoclonal Antibodies)
• Interferon beta-1a (Interferon)
• LSALT Peptide (Antiviral)
• Remdesivir (Antiviral)

Trial Overview The trial is testing multiple treatments: Artesunate, Imatinib, Infliximab, Dexamethasone (a steroid), and LSALT Peptide in an adaptive design. Patients are randomly assigned to receive one of these interventions alongside standard care for COVID-19.

Participant Groups

Group I: LSALT Peptide Experimental Treatment 1 Intervention

Subjects will be randomized between LSALT vs standard of care.

Group II: Infliximab Experimental Treatment 1 Intervention

Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care

Group III: Imatinib Experimental Treatment 1 Intervention

Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care

Group IV: Dexamethasone Experimental Treatment 1 Intervention

Subjects will be randomized between Dexamethasone vs standard of care.

Group V: Artesunate Experimental Treatment 1 Intervention

Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care

Group VI: Control (Standard Care) Active Control 1 Intervention

This arm will receive standard supportive care guidelines for COVID-19. It is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.

Who Is Running the Clinical Trial?

Sunnybrook Health Sciences Centre

Lead Sponsor

Trials

693

Recruited

1,569,000+

Dr. Rajin Mehta

Sunnybrook Health Sciences Centre

Chief Medical Officer

MD from University of Toronto

Dr. Andrew J. Smith

Sunnybrook Health Sciences Centre

President and CEO since 2017

MD, MSc from University of Toronto; Surgical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center

AbbVie

Industry Sponsor

Trials

1,079

Recruited

535,000+

Founded

2013

Headquarters

North Chicago, USA

Known For

Immunology treatments

Top Products

Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib)

Dr. Roopal Thakkar

AbbVie

Chief Medical Officer since 2023

MD from Wayne State University School of Medicine

Robert A. Michael

AbbVie

Chief Executive Officer

Bachelor's degree in Finance from the University of Illinois

Apotex Inc.

Industry Sponsor

Trials

9

Recruited

29,000+

World Health Organization

Collaborator

Trials

236

Recruited

1,620,000+

Dr. Hiroshi Nakajima

World Health Organization

Chief Medical Officer since 1988

MD from University of Tokyo

Dr. Tedros Adhanom Ghebreyesus

World Health Organization

Chief Executive Officer since 2017

PhD in Community Health from the University of Nottingham, MSc in Immunology of Infectious Diseases from the University of London, BSc in Biology from the University of Asmara

University of British Columbia

Collaborator

Trials

1,506

Recruited

2,528,000+

Dr. Christopher Haqq

University of British Columbia

Chief Medical Officer since 2019

MD, University of British Columbia

Bekki Bracken Brown

University of British Columbia

Chief Executive Officer since 2023

Bachelor's degree from Duke University

Arch Biopartners Inc.

Industry Sponsor

Trials

4

Recruited

3,300+